The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2024

Filed:

Sep. 22, 2017
Applicant:

Macfarlane Burnet Institute for Medical Research and Public Health Limited, Melbourne, AU;

Inventors:

Heidi Drummer, Melbourne, AU;

Pantelis Poumbourios, Melbourne, AU;

Robert Center, Melbourne, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/113 (2006.01); A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61P 31/14 (2006.01); C07K 1/13 (2006.01); C07K 1/22 (2006.01); C07K 14/005 (2006.01); C07K 14/18 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/576 (2006.01); A61K 39/00 (2006.01); C07K 16/10 (2006.01);
U.S. Cl.
CPC ...
C07K 1/1133 (2013.01); A61K 39/12 (2013.01); A61K 39/29 (2013.01); A61P 31/14 (2018.01); C07K 1/1136 (2013.01); C07K 1/13 (2013.01); C07K 1/22 (2013.01); C07K 14/005 (2013.01); C07K 14/1833 (2013.01); G01N 33/5047 (2013.01); G01N 33/5052 (2013.01); G01N 33/56966 (2013.01); G01N 33/5767 (2013.01); A61K 2039/645 (2013.01); C07K 16/109 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C12N 2770/24222 (2013.01); C12N 2770/24234 (2013.01);
Abstract

A method of preparing extracellularly assembled higher order antigen from a native lower order antigen the method comprising the following steps: (i) contacting lower order antigen with a solution comprising a reducing agent for a time and under 5 conditions sufficient to reduce one or more native cysteines; and (ii) removing or diluting the reducing agent or contacting the reduced lower order antigen with an oxidising agent, to elicit assembly of lower order antigen from (i) into an assembled higher order antigen; wherein at least 10% of the lower order antigen is converted to higher order antigen in step (ii) and whereby the assembled higher order antigen 10 displays at least reduced binding to non-neutralizing antibodies compared to the lower order antigen and retains binding to at least one neutralizing antibody. A method of producing a vaccine composition comprising following the steps of the method and then mixing the assembled higher order antigen with a pharmaceutically or physiologically acceptable diluent, carrier or adjuvant. A composition comprising a 15 higher order extracellularly assembled antigen, wherein the assembled antigen displays at least reduced binding to a non-neutralizing antibody compared to a native control higher order antigen. Use of the assembled higher order antigen to stimulate an immune response or for the detection and/or isolation of an immune cell such as a B-cell specific for the antigen.


Find Patent Forward Citations

Loading…